Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action

Blood Coagulation and Fibrinolysis

Volumn 14, Issue 2, 2003, Pages 159-167

  Nylander, Sven ^a   Mattsson, Christer ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Direct thrombin inhibitor; Flow cytometry; GP1b melagatran; P selectin; PAR 1; PAR 4; Platelets; Thrombin; Ximelagatran

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; GLYCOPROTEIN IB; HEPARIN; HIRUDIN; INOGATRAN; MELAGATRAN; PADGEM PROTEIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 4; THROMBIN;

ANTICOAGULATION; ARTICLE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; GENE CONTROL; HUMAN; HUMAN CELL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; THROMBOCYTE ACTIVATION; UPREGULATION;

ADULT; ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; DALTEPARIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GLYCINE; HEPARIN; HIRUDINS; HUMANS; MALE; P-SELECTIN; PIPERIDINES; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; RECEPTOR, PAR-1; RECEPTORS, THROMBIN; STATISTICS; THROMBIN;

EID: 0037297332     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200302000-00007     Document Type: Article

References (31)

1. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64:1057-1068.
2. Ishihara H, Connoly AJ, Zeng D, Kahn ML, Zheng YW, et al. Protease-activated receptor 3 is a second receptor in humans. Nature 1997; 386:502-506.
3. Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci USA 1998; 95:6642-6646.
4. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103:879-887.
5. Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Nat Acad Sci USA 1999; 96:11189-11193.
6. Covic L, Gresser AL, Kuliopulos A. Biphasic kinetics of activation and signaling for PAR-1 and PAR-4 thrombin receptors in platelets. Biochemistry 2000; 39:5458-5467.
7. Ayala YM, Cantwell AM, Rose T, Bush LA, Arosio D, Di Cera E. Molecular mapping of thrombin-receptor interactions, Proteins 2001; 45:107-116.
8. De Marco L, Mazzucato M, Masotti A, Ruggeri ZM. Localization and characterization of an α-thrombin binding site on platelet glycoprotein Ibα. J Biol Chem 1994; 269:6478-6484.
9. Mazzucato M, De Marco L, Masotti A, Pradella P, Bahou WF, Ruggeri ZM, Characterization of the initial alpha-thrombin interaction with glycoprotein Ib alpha in relation to platelet activation. J Biol Chem 1998; 273:1880-1887.
10. Handa M, Titani K, Holland LZ, Roberts JR, Ruggeri ZM. The von Willebrand factor-binding domain of platelet membrane glycoprotein Ib: characterization by monoclonal antibodies and partial amino acid sequence analysis of proteolytic fragments. J Biol Chem 1986; 261:12579-12585.
11. De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of PAR-1 on intact platelets. J Biol Chem 2001; 276:4692-4698.
12. De Candia E, De Cristofaro R, Landolfi R, Thrombin-induced platelet activation is inhibited by high- and low-molecular-weight heparin. Circulation 1999; 99:3308-3314.
13. Ramakrishnan V, De Guzman F, Bao M, Hall SW, Leung LL, Phillips DR. A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V. Proc Nat Acad Sci USA 2001; 98:1823-1828.
14. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor on thrombin and fibrinolytic enzymes. Thromb Haemost 1998; 79:110-118.
15. Gustafsson D, Nystrom J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101:171-181.
16. Teger-Nilsson A-C, Bylund R, Gustafsson D, Gyzander E, Eriksson U. In vitro effects of inogatran. A selective low molecular weight thrombin inhibitor. Thromb Res 1997; 85:133-145.
17. Braun PJ, Dennis S, Hofsteenge J, Stone SR. Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin. Biochemistry 1988; 27:6517-6522.
18. Hirsh J, Warkentin TE, Shaughnessy SG, Anand S, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119:64S-94S.
19. Michelson AD, Barnard MR, Krueger LA, Frelinger AL 3rd, Furman MI. Evaluation of platelet function by flow cytometry. Methods 2000; 21:259-270.
20. Michelson AD. Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: methods and clinical applications. Blood Coagul Fibrinolysis 1994; 5:121-131.
21. Brass LF, Pizarro S, Ahuja M, Belmonte E, Blanchard N, Stadel JM, et al. Changes in the structure and function of the human thrombin receptor during receptor activation, internalization, and recycling. J Biol Chem 1994; 269:2943-2952.
22. Molino M, Blanchard N, Belmomte E, Tarver AP, Abrams AP, Hoxie JA, et al. Proteolysis of the human platelet and endothelial cell thrombin receptor by neutrophil-derived cathepsin G. J Biol Chem 1995; 270:11168-11175.
23. Molino M, Bainton DF, Hoxie JA, Coughlin SR, Brass LF. Thrombin receptors on human platelets. Initial localization and subsequent redistribution during platelet activation. J Biol Chem 1997; 272:6011-6017.
24. Barrowcliffe T. Heparin assays and standardization. In: Lane DA, Lindahl U (editors). Heparin chemical and biological properties. London: Hodder and Stoughton; 1989. pp. 393-415.
25. Covic L, Singh C, Smith H, Kuliopulos A. Role of the PAR-4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak Syndrome. Thromb Haemost 2002; 87:722-727.
26. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97:251-256.
27. Jacques SL, Le Masurier M, Sheridan PJ, Seeley SK, Kuliopulos A. Substrate-assisted catalysis of the PAR-1 thrombin receptor: enhancement of macromolecular association and cleavage. J Biol Chem 2000; 275:40671-40678.
28. Chung AWY, Jurasz P, Hollenberg MD, Radomski MW. Mechanisms of action of proteinase-activated receptor agonists on human platelets. Br J Pharmacol 2002; 135:1123-1132.
29. Klement P, Carlsson S, Liao P, Vlasin M, Stafford A, Johnston M, et al. Melagatran, the active form of the oral direct thrombin inhibitor ximelagatran: an alternative to hirudin in prevention of arterial thrombosis with a wider therapeutic window [Abstract]. Blood 2001; 98:41a.
30. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001; 413:74-78.
31. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. PAR-3 is a cofactor for PAR-4 activation by thrombin. Nature 2000; 404:609-613.